Sveriges mest populära poddar
Behind the Money
NyheterNäringsliv

Pharma raises its bet on biotech

19 min•15 januari 2019

In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. 


Read more from Sarah at FT.com.

Hosted on Acast. See acast.com/privacy for more information.

Fler avsnitt av Behind the Money

Visa alla avsnitt av Behind the Money
Finale: The collapse of India’s $22bn tech star
•31 min
Private credit’s public reckoning
•27 min
Best of: How the diamond industry lost its sparkle
•24 min
Introducing Untold: Opus Dei
•1 min
Wall Street and crypto battle over the future of money
•20 min
Vote for Behind the Money in the NYC Podcast Awards!
•1 min
Co-creators Mickey Down & Konrad Kay on ‘Industry’
•32 min
Companies reap $22bn from Trump’s immigration crackdown
•26 min
How a private equity pioneer lost its grip on the market it invented
•19 min
A hedge fund’s $8bn bet on Venezuela’s Citgo
•20 min

Behind the Money med Financial Times finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.